This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Conmed (CNMD) Down 2.8% Since Last Earnings Report?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CONMED (CNMD) Beats Earnings, Revenue Estimates in Q3
by Zacks Equity Research
Solid domestic and international sales drive CONMED's (CNMD) results in Q3. Also, raised sales guidance encourages.
Conmed (CNMD) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 2.22% and 1.72%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Conmed (CNMD) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold CONMED Stock in Your Portfolio
by Zacks Equity Research
Despite aggressive rivalry in the MedTech space, CONMED (CNMD) to gain from its unique offerings and an extensive product portfolio.
CONMED (CNMD) Beats on Q2 Earnings, Raises 2018 Guidance
by Zacks Equity Research
CONMED (CNMD) sees solid domestic and international sales in Q2; raised guidance encourages.
Conmed (CNMD) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 2.22% and 2.88%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
CONMED (CNMD) Up 9.1% Since Earnings Report: Can It Continue?
by Zacks Equity Research
CONMED (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CONMED (CNMD) Beats on Q1 Earnings, Lifts FY18 Guidance
by Zacks Equity Research
CONMED (CNMD) gains on strong performance in core segments; raised guidance buoys optimism.
5 Reasons Why You Should Buy CONMED (CNMD) Stock Right Now
by Zacks Equity Research
Strong market trends and share price performance fortify CONMED's (CNMD) foothold in the niche markets.
Conmed (CNMD) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Conmed (CNMD) benefits from impressive general surgery performance and enhanced innovation in Q4.
CONMED (CNMD) Q3 Earnings and Revenues Beat, Margin Down
by Zacks Equity Research
CONMED (CNMD) gains from strength in General Surgery business in Q3, driven by strong performances by Advanced Surgical and Endoscopic Technologies.
Why Is CONMED (CNMD) Down 2.9% Since the Last Earnings Report?
by Zacks Equity Research
CONMED (CNMD) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
CONMED (CNMD) Earnings Meet, Revenues Beat Estimates in Q2
by Zacks Equity Research
CONMED's (CNMD) strong global performance was a key highlight in the second quarter of 2017.
CONMED (CNMD) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Shares of Utica, NY-based leading medical technology player, CONMED Corporation (CNMD) rallied to a new 52-week high of $52.79 on Jun 13, closing a little lower at $52.49.
CONMED (CNMD) Q1 Earnings Surpass Estimates, Increase Y/Y
by Zacks Equity Research
CONMED Corporation (CNMD) reported first-quarter 2017 adjusted earnings of 38 cents per share, beating the Zacks Consensus Estimate by 4 cents.
New Strong Sell Stocks for February 8th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
CONMED (CNMD) Q4 Earnings Miss Estimates, Increase Y/Y
by Zacks Equity Research
Headquartered in Utica, NY, leading medical technology player, CONMED Corporation (CNMD) reported fourth-quarter 2016 adjusted earnings of 54 cents per share, missing the Zacks Consensus Estimate by 2 cents.